Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Custom Media Event: ESG Summit
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Transformation Summit
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain Revenue Cycle
    • - Hospital at Home
    • - Workplace of the Future
    • - Virtual Health
    • - Future of Healthcare Staffing
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Technology
December 10, 2014 12:00 AM

Antitrust suit accuses Sovaldi maker Gilead of price-gouging

Lisa Schencker
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    Gilead Sciences' eye-popping $1,000-a-pill cost for its hepatitis C drug Sovaldi is illegal price-gouging with the potential to bankrupt parts of the healthcare industry, according to a lawsuit filed in federal court Tuesday.

    The proposed class-action lawsuit, filed by the Southeastern Pennsylvania Transportation Authority in U.S. District Court in Philadelphia, accuses Gilead of antitrust violations, unjust enrichment and discrimination against those who need the drug and can't afford it, among other claims.

    Gilead spokeswoman Michele Rest declined Wednesday morning to comment on the lawsuit, saying the company had just received the complaint. During a July earnings call, Gilead CEO John Martin said that as more people are cured of hepatitis C, concerns over the price will fade.

    “Over time, the healthcare system will save a lot of money by these patients being healthy again,” Martin said during the earnings call.

    But Ben Johns, a partner at Chimicles & Tikellis in Haverford, Pa., representing the plaintiff, said the price is a roadblock to those who need it most.

    “This is an extraordinary drug, and we would like to do everything that can be done to make sure this gets out to people that need it and can benefit from it without potentially bankrupting segments of the healthcare industry,” Johns said.

    The lawsuit alleges that the plaintiff, the Southeastern Pennsylvania Transportation Authority, already has paid more than $2.4 million for Sovaldi for its members.

    Gilead's Sovaldi, which was approved by the Food and Drug Administration in late 2013, has a cure rate of more than 90%—significantly higher than the 40% cure rate of previous treatments for hepatitis C. But the drug costs $84,000 for a 12-week course of treatment, rattling many payers and prompting most states to implement prior authorization restrictions.

    About 3 million Americans have chronic hepatitis C, a liver disease that can cause cirrhosis or liver cancer.

    The complaint notes that given the large number of people suffering from hepatitis C in the U.S., Gilead doesn't need to charge so much for the drug.

    “Unlike other specialty drugs that come with comparable hefty price tags—but only affect a small number of patients—there are several million Americans living with hepatitis-C that could benefit from this drug,” according to the complaint. “If Gilead's conduct is left unchecked, many of these patients will never get access to this drug and, in those cases where they do, third-party payors like plaintiff will continue to pay exorbitant prices for Sovaldi.”

    Leaders of the Senate Finance Committee in July sent a letter to Gilead requesting pricing information on the drug, saying: “In order for a marketplace to function properly, it must be competitive, fair and transparent. It is unclear how Gilead set the price for Sovaldi.”

    In a July statement, Brendan Buck, a spokesman for America's Health Insurance Plans, said Gilead should be rewarded for the “breakthrough” drug, “But the current price cannot be justified by development costs; it's purely a reflection of Gilead believing that it has a blank check.”

    In the third quarter of this year, sales of Sovaldi made up about 47% of Gilead's total revenue, generating about $2.8 billion. Gilead also sells another hepatitis C drug, Harvoni, that costs $94,500 for a 12-week course of treatment.

    Follow Lisa Schencker on Twitter: @lschencker

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Amwell logo_edited_i.jpg
    Amwell tapped for CVS Health's virtual care platform
    Myra Davis
    Q&A with Myra Davis of Texas Children's Hospital: ‘Innovation is everyone’s responsibility’
    Sponsored Content
    Health IT Strategist (HITS) Newsletter: Sign up for the latest IT and medical technology news delivered 3 days a week (M, W, F).
     
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2022. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Transformation Summit
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain Revenue Cycle
        • - Hospital at Home
        • - Workplace of the Future
        • - Virtual Health
        • - Future of Healthcare Staffing
      • Custom Media Event: ESG Summit
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing